How This Pharma Company Can Benefit From Its Competitors
Delays in FDA approval for Incyte could spell good news for Sanofi.
Mindfully Curated
Delays in FDA approval for Incyte could spell good news for Sanofi.
One of these agreements could be more important than the other.
Investors have many ways to play the renewable energy megatrend.
One is Biogen’s partner. The other is a potential rival.
Why this company is so well-positioned to thrive.
NVIDIA could become the biggest company in the world.
The pure-play streaming-TV company’s expertise in connected TV, combined with its latest investments, is paying off nicely.
These strategies can help make the most of your money.
In the big data “gold rush,” this company sells picks and shovels.
It’s important to know the underlying company before you choose an options strategy on a stock.
Its growth trajectory is ready to accelerate.
This low-profile manufacturer serves the booming semiconductor industry, and it’s growing nicely.
These investments could deliver big wins through the next decade and beyond.
These shares yielding between 2% and 7% are some of the surest bets in the energy sector today.
AppFolio’s recent numbers aren’t thrilling, but could that change?
They are designed to generate steady dividends at high yields, with great long-term returns as a bonus.
The Pentagon is starting to budget to take advantage of a SpaceX rocket delivery service from Earth… to Earth.
Citizens Financial is hoping to make more on interest-earning assets, and pay out less on interest-bearing liabilities.
There are different retirement savings plans you can choose from. If you’re contemplating a Roth IRA, here’s what you need to know.
Three choices for investors who are looking to the skies for stock ideas.